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Polyunsaturated fatty acids (PUFAs) exhibit a range of biological effects, many of which are mediated
through the formation and actions of their bioactive metabolites. It is well appreciated that dietary PUFA
balance affects inﬂammation and/or allergic diseases, and recent advances in liquid chromatography
tandem mass spectrometry (LC-MS/MS)-based mediator lipidomics have revealed a potential link be-
tween PUFA metabolism and biological phenotypes. This review presents insights into the emerging
roles of eosinophil PUFA metabolism in controlling inﬂammatory responses and its potential involve-
ment in allergy control.
Copyright © 2016, Japanese Society of Allergology. Production and hosting by Elsevier B.V. This is an open access
article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).PUFA metabolism and regulation of inﬂammation
PUFA metabolism is recognized as an important factor in im-
mune regulation and disease control. In particular, the metabolic
balance between n-6 and n-3 PUFAs is widely held to be important
in human health and diseases. PUFA-derived bioactive metabolites
are formed in vivo by enzymatic oxidation through the action of
cyclooxygenases (COX), lipoxygenases (LOX), and cytochrome P450
monooxygenases (CYP). From n-6 PUFAs, e.g., arachidonic acid, the
COX pathway leads to the formation of prostaglandins (PG) andtegrative Medical Sciences, 1-
230-0045, Japan.
ety of Allergology.
rgology. Production and hosting by Elsethromboxanes, the LOX pathway leads to leukotrienes (LT) and
lipoxins (LX), and the CYP pathway leads to hydroxy-
eicosatetraenoic acids (HETE) and epoxy-eicosatrienoic acids
(EET).1,2 In general, COX-derived PGs and 5-LOX-derived LTs are
involved in the initiation of inﬂammatory responses, whereas 12/
15-LOX-derived LXs counter-regulate the inﬂammatory processes
and may be involved in the resolution of inﬂammation. The CYP
pathway generates EETs, which may have roles in regulation of
inﬂammation and vascular tone.
Eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA)
are n-3 PUFAs, and dietary supplementation with such compounds
is widely held to have beneﬁcial effects in many inﬂammatory
disorders.3 Consistently, elevation of tissue n-3 PUFA levels in fatty
acid n-3 desaturase (fat-1) transgenic mice is protective in many
disease models.4,5 EPA and DHA are good substrates for LOX and
CYP, and thus can be efﬁciently converted into bioactivevier B.V. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/
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and maresins.6 The n-3 PUFAs are thought to play anti-
inﬂammatory and tissue protective roles via several mechanisms;
by competing with the arachidonate cascade to attenuate the for-
mation and action of pro-inﬂammatory eicosanoids (e.g., PGs and
LTs), or by being converted to potent anti-inﬂammatory and/or pro-
resolving mediators such as resolvins and protectins (Fig. 1). Thus,
to elucidate the molecular mechanisms underlying the importance
of PUFA balance and to gain a comprehensive understanding of
their physiological and/or pathophysiological roles, it is important
to knowwhen, where and howmuch of these PUFAmetabolites are
formed in inﬂammatory sites. To this end, we developed a LC-MS/
MS-based mediator lipidomics system that can detect and quan-
tify more than 500 PUFA metabolites simultaneously.1
Eosinophils control inﬂammatory responses via lipid signals
Acute inﬂammation is an important host defense mechanism,
and its proper resolution is required to maintain homeostasis.7 The
resolution of inﬂammation involves active cellular and molecular
programs that enable inﬂamed tissues to return to their homeo-
static state. The mechanisms by which acute inﬂammation is
resolved are of interest to both basic scientists and clinicians, and
research in recent years has uncovered novel endogenous mecha-
nisms that involve 12/15-LOX-expressing eosinophils in controlling
resolution of inﬂammation.8
LC-MS/MS-based mediator lipidomics revealed temporal
changes in PUFA metabolites during the course of acute inﬂam-
mation and resolution. The highest levels of COX- and 5-LOX-
derived mediators such as PGE2 and LTB4 were observed during the
initiation phase, and the formation of 12/15-LOX-derivedmediators
such as LXA4 and protectin D1 was increased during the resolution
phase of acute peritonitis.8,9 In the resolution phase, eosinophils
were the major cell type expressing 12/15-LOX. The in vivo deple-
tion of eosinophils signiﬁcantly reduced 12/15-LOX products in
resolving exudates and caused a resolution defect characterized by
impaired lymphatic drainage to draining lymph nodes (DLNs),Fig. 1. Lipid mediators that regulate inﬂammatory responses. In addition to arachidonic acid
mediators such as LXs and n-3 PUFA-derived resolvins and protectins are also produced. Talong with increased polymorphonuclear leukocyte (PMN)
numbers in inﬂamed sites. Furthermore, the resolution deﬁcit
caused by eosinophil depletion was rescued by adoptive transfer of
eosinophils, but eosinophils deﬁcient in 12/15-LOX were unable to
rescue the resolution phenotype. These results indicated that eo-
sinophils are recruited to the inﬂamed site, where they locally
produce pro-resolving mediators via a 12/15-LOX-initiated
biosynthetic route and play roles in promoting resolution of acute
inﬂammation (Fig. 2).8
Macrophages play important roles in the resolution of inﬂam-
mation by efﬁcient clearance of apoptotic cells and/or tissue debris
from inﬂamed sites, and thereby facilitate the return of the tissue to
a state of homeostasis. 12/15-LOX-expressing eosinophils promote
resolution of acute peritonitis by regulating gene expression pat-
terns in macrophages. Microarray analysis revealed that eosino-
phils signiﬁcantly increased the expression of macrophage CXCL13
by a 12/15-LOX-dependent mechanism.10 CXCL13 was expressed in
a subset of macrophages present in the resolution phase, and mice
treated with anti-CXCL13 antibody displayed a resolution deﬁcit,
with reduced lymphatic drainage to DLNs. It is well established that
CXCL13 is a functional chemokine in the early development of
peripheral lymph nodes.11 Since lymphatic drainage is involved in
promoting inﬂammatory cell clearance from the periphery, we
questioned whether 12/15-LOX-expressing eosinophils actively
contribute to this process. Analysis of the cellular composition of
the inﬂamed DLNs revealed that eosinophils were present, and that
their depletion or 12/15-LOX deﬁciency resulted in reduced
numbers of every immune cell component examined, including
lymphocytes, macrophages, PMNs and dendritic cells. Adoptive
transfer of eosinophils, or administration of recombinant CXCL13,
restored the inﬂamed DLN expansion with increased cell numbers.
These results demonstrated that 12/15-LOX-expressing eosinophils
control inﬂamed DLN hypertrophy through the CXCL13 pathway in
mice (Fig. 2). It is possible that eosinophils actively promote DLN
remodeling and expansion that could in turn drive lymphatic
drainage and efﬁcient clearance of inﬂammatory exudates from
peripheral tissues.10-derived mediators such as COX-derived PGs and 5-LOX-derived LTs, 12/15-LOX-derived
hese mediators play important roles in regulating inﬂammatory responses.
Fig. 2. Eosinophils promote resolution of acute inﬂammation via lipid signals. Eosinophils are recruited in the early resolution phase, where they locally produce resolution
mediators via a 12/15-LOX-initiated biosynthetic route, and play roles leading to the efﬁcient clearance of inﬂammatory exudates via lymphatic drainage. 12/15-LOX-expressing
eosinophils control inﬂamed DLN hypertrophy, which is important for inﬂammatory cell clearance, through the CXCL13 pathway.
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Eosinophils serve as innate immune cells by producing pro-
inﬂammatory lipid mediators such as leukotrienes and platelet
activating factor (PAF), but as described above, eosinophils also
express relatively high level of 12/15-LOX and produce anti-
inﬂammatory mediators. Therefore imbalanced PUFA metabolism
in eosinophils could be involved in disease pathogenesis especially
when sustained inﬂammation is suspected as a key component of
pathogenesis. A human clinical study revealed impaired 15-LOX
activity in eosinophils isolated from severe asthmatic patients as
compared to healthy controls (Fig. 3).12 This observation is consis-
tent with other reports13e15 suggesting that PUFA metabolism is
dysregulated in eosinophils and that this could contribute to dis-
ease pathogenesis in severe asthmatics. Further multi-omics
studies are ongoing by our group to identify transcripts, proteinsFig. 3. Impaired 15-LOX activity in eosinophils from severe asthmatics. Peripheral blood eosi
of the n-3 PUFA docosahexaenoic acid (DHA). The levels of PUFA metabolites were measurand metabolites differentially expressed in eosinophils isolated
from allergy patients, determining the presence of eosinophil
heterogeneity (i.e. hypodense eosinophils etc.) as reported
previously.16,17
Mediator lipidomics have also revealed that the 12/15-LOX-
mediated pathway is an important host defense mechanism to
protect against inﬂuenza virus infection.18 12/15-LOX-deﬁcient
mice were more susceptible to severe symptoms of inﬂuenza virus
infection, and administration of 12/15-LOX-derived products
reduced inﬂuenza virus replication by interfering with nuclear
export of viral RNA in cultured cells. Protective effects were also
seen in vivo, where administration of a PUFA-derived lipidmediator
improved the pathology and survival rate. These results indicate
that the 12/15-LOX pathway is protective against inﬂuenza virus
infection, and that 12/15-LOX-derived PUFA metabolites could be
used in the development of novel therapeutics.nophils were stimulated with the calcium ionophore A23187 in the presence or absence
ed by LC-MS/MS.12
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also supported by other disease models. It is well established that
eosinophils reside in the colonic mucosa, and it was reported that
eosinophil-deﬁcient mice developed more severe colitis, and their
colon tissues contained a greater number of neutrophils.19 Lip-
idomic analyses of colonic tissue from eosinophil-deﬁcient mice
identiﬁed a deﬁciency in 12/15-LOX-derived mediators, moreover,
administration of a 12/15-LOX product to eosinophil-deﬁcient mice
reduced the disease severity.
Perspectives
Eosinophils are involved in the innate immune response to
helminth infection and also in allergic responses.20 Recently, eo-
sinophils were shown to play homeostatic roles in adipose tissue,
skeletal muscle, liver and small intestine.21e24 In this brief review,
we presented insights into the emerging role of eosinophils as pro-
resolving and tissue protective effector cells via the 12/15-LOX-
mediated pathway. This is a novel and important endogenous
mechanism that properly brings acute inﬂammation to a close, and
is potentially related to clinical ﬁndings of dysregulated 12/15-LOX
activity in eosinophils from patients with severe asthma.12
Besides eosinophils, 12/15-LOX is expressed in a subset of
macrophages and airway epithelial cells.25 12/15-LOX-expressing
macrophages are present in the peritoneal cavity of naïve mice and
also during the resolution phase of acute peritonitis. These cells
display competent phagocytic activity that potentially contributes
to tissue homeostasis by efﬁcient clearance of apoptotic cells.26
Cells expressing 12/15-LOX may be involved in regulating inﬂam-
matory responses by locally producing anti-inﬂammatory and/or
pro-resolving lipid mediators. This model is consistent with the
ﬁndings in disease models of inﬂammatory phenotypes and
impaired host defense in 12/15-LOX-deﬁcient mice.26e29
Mediator lipidomics deals with the simultaneous and quanti-
tative analysis of bioactive lipid mediators in biological systems.
When combined with multi-omics proﬁling, it can greatly assist in
understanding the role of PUFAmetabolism in certain physiological
or pathophysiological conditions. This technology could potentially
identify the metabolic ﬁngerprint of a particular disease for clinical
diagnosis and treatment. Moreover, identiﬁcation of endogenous
anti-inﬂammatory and/or pro-resolving lipid signals4,30,31 and
elucidation of their molecular mechanisms should lead to the
development of novel therapeutics for inﬂammatory diseases.
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